Supplementary Figure S6 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

Supplementary Figure S6. The combination of JAB-3312 and EGFR inhibitor osimertinib synergistically inhibited cancer cell growth in vitro and did not affect the weight gain of mice. A-B. Proliferation inhibition of NCI-H1975 (A) and NCI-H1975-C797S (B) human lung cancer cells by JAB-3312, osimertinib, or their combination. C-D. The body weight change of NCI-H1975 (C) and LUN#2355-214 (D) xenograft models during the treatment of JAB-3312, osimertinib, and the two-drug combination. Mean ± SEM was shown.